Author’s response to reviews

Title: In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Authors:

Julie Parmentier (julie.parmentier@abbvie.com)
Jeff Voss (Jeffwvoss@netscape.net)
Candace Graff (candace.graff@abbvie.com)
Annette Schwartz (annette.schwartz@abbvie.com)
Maria Argiriadi (maria.argiriardi@abbvie.com)
Michael Friedman (michael.friedman@abbvie.com)
Heidi Camp (heidi.camp@abbvie.com)
Robert Padley (rjpadley@comcast.net)
Jonathan George (jonathan.george@abbvie.com)
Deborah Hyland (deborah.hyland@abbvie.com)
Matthew Rosebraugh (matthew.rosebraugh@abbvie.com)
Neil Wishart (nwishart34@gmail.com)
Lisa Olson (lisaolson@abbvie.com)
Andrew Long (andrew.long@abbvie.com)

Version: 2 Date: 31 May 2018

Author’s response to reviews:

Dear Editorial Staff,

Thank you for the review and notification of the acceptance pending revision. The editorial suggestions are listed below with the response below indicated as "response". Please let us know if there is anything additional that you need.

Sincerely,

Andrew Long
1. In the Ethics approval and consent to participate section of the Declarations, please provide the full name (not abbreviated) of the Ethics committee that approved your study.

Response: On page 21, PPD Development, LLC has been changed to Pharmaceutical Product Development, LLC per request

2. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Response: The manuscript has been reviewed and the uploaded version is the final, clean version